Late-stage biotech company developing potentially curative gene therapies through leveraging its proprietary NAV technology (consists of novel AAV vectors) Generates significant revenue through … [Read more...] about Regenxbio (RGNX)-About
gene therapy
Gene Therapy Exciting, But Early
Gene therapy involves inserting genetic material into cells to prevent, cure, or correct a disease caused by genetic abnormalities whereas gene editing involves making actual changes to the genetic … [Read more...] about Gene Therapy Exciting, But Early
BLCM #VolatilityWatch
Bellicum Pharmaceuticals (NASDAQ: BLCM) has been in continuous long-term downtrend since IPO. Stock price has been showing signs of a bottom (starting Aug 2019 to current) and with very successful … [Read more...] about BLCM #VolatilityWatch
Incoming Data + Gartley
Friday, October 11, 2019 About: ADVERUM BIOTECHNOLOGIES INC (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ADVM is set … [Read more...] about Incoming Data + Gartley
Biotech: Time To Buy the Bull
As the month of October begins and broader markets sold off, biotech stocks are still largely negative and/ or flat for the year. As seen in the LABU vs. LABD chart below, the spread between the two … [Read more...] about Biotech: Time To Buy the Bull
Sangamo Therapeutics Inc.(Nasdaq: SGMO) – Doom Or Gloom Scenario
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company … [Read more...] about Sangamo Therapeutics Inc.(Nasdaq: SGMO) – Doom Or Gloom Scenario
My #1 Mid-Cap Biotech Stock Pick For 2019
The four qualities that I assign the most weight when evaluating a biotech company for viability is 1) An efficacious product 2) Sufficient funding 3) Competent leadership and 4) Relationships with … [Read more...] about My #1 Mid-Cap Biotech Stock Pick For 2019
You must be logged in to post a comment.